AU2020229381A1 - Novel iron compositions and methods of making and using the same - Google Patents

Novel iron compositions and methods of making and using the same Download PDF

Info

Publication number
AU2020229381A1
AU2020229381A1 AU2020229381A AU2020229381A AU2020229381A1 AU 2020229381 A1 AU2020229381 A1 AU 2020229381A1 AU 2020229381 A AU2020229381 A AU 2020229381A AU 2020229381 A AU2020229381 A AU 2020229381A AU 2020229381 A1 AU2020229381 A1 AU 2020229381A1
Authority
AU
Australia
Prior art keywords
composition
iron
aqueous
sucrose
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020229381A
Other languages
English (en)
Inventor
Alvaro F. Guillem
Donald Jeffrey Keyser
Richard A. ZAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renibus Therapeutics Inc
Original Assignee
Renibus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics Inc filed Critical Renibus Therapeutics Inc
Publication of AU2020229381A1 publication Critical patent/AU2020229381A1/en
Priority to AU2025230678A priority Critical patent/AU2025230678A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020229381A 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same Abandoned AU2020229381A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025230678A AU2025230678A1 (en) 2019-02-28 2025-09-10 Novel iron compositions and methods of making and using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812028P 2019-02-28 2019-02-28
US62/812,028 2019-02-28
PCT/US2020/020517 WO2020176894A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025230678A Division AU2025230678A1 (en) 2019-02-28 2025-09-10 Novel iron compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2020229381A1 true AU2020229381A1 (en) 2021-09-16

Family

ID=70190086

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020229381A Abandoned AU2020229381A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same
AU2025230678A Pending AU2025230678A1 (en) 2019-02-28 2025-09-10 Novel iron compositions and methods of making and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025230678A Pending AU2025230678A1 (en) 2019-02-28 2025-09-10 Novel iron compositions and methods of making and using the same

Country Status (20)

Country Link
US (4) US11292813B2 (enExample)
EP (2) EP4234020A3 (enExample)
JP (3) JP7320611B2 (enExample)
KR (1) KR20210133243A (enExample)
CN (2) CN119488480A (enExample)
AU (2) AU2020229381A1 (enExample)
CA (1) CA3131596A1 (enExample)
DK (1) DK3930686T3 (enExample)
ES (1) ES2955019T3 (enExample)
FI (1) FI3930686T3 (enExample)
HR (1) HRP20230989T1 (enExample)
HU (1) HUE063182T2 (enExample)
LT (1) LT3930686T (enExample)
PL (1) PL3930686T3 (enExample)
PT (1) PT3930686T (enExample)
RS (1) RS64652B1 (enExample)
SG (1) SG11202109323UA (enExample)
SI (1) SI3930686T1 (enExample)
SM (1) SMT202300276T1 (enExample)
WO (1) WO2020176894A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541606A (ja) * 2020-09-11 2023-10-03 レニバス・セラピューティクス・インコーポレイテッド 腎臓を保護しながらがんを治療するための方法
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN115969714B (zh) * 2022-11-03 2025-03-11 华熙生物科技股份有限公司 具有光谱选择性的防晒组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE862482C (de) * 1950-05-14 1953-01-12 Merck Chem Fab E Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US7300674B2 (en) * 2000-12-20 2007-11-27 Sheldon Tobe Sterile low bicarbonate dialysis concentrate solutions
ES2315401T3 (es) * 2002-08-26 2009-04-01 Vifor (International) Ag Prueba de bioequivalencia para formulaciones que contienen hierro.
US7674780B2 (en) * 2004-03-16 2010-03-09 Navinta Llc Iron sucrose complexes and method of manufacture thereof
ES2424943T3 (es) 2004-12-06 2013-10-10 Emcure Pharmaceuticals Limited Un proceso rentable para la preparación de hierro sacarosa
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
RS52185B (sr) 2006-10-04 2012-10-31 Infacare Pharmaceutical Corporation Preparat stansoporfina sa visokim stepenom čistoće
EP1947120A1 (de) 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
IN269965B (enExample) 2007-06-25 2015-11-27 Claris Lifescienses Ltd
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
AU2010220396B2 (en) 2009-03-02 2013-10-17 Vifor (International) Ag Phosphate adsorbent
CN102451185A (zh) * 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
EP2647389A1 (en) * 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
CN103340827B (zh) * 2013-07-16 2014-12-10 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) * 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法
IN2013CH05383A (enExample) 2013-11-21 2015-08-28 Reddy’S Lab Ltd Dr
CN104098616B (zh) 2014-05-27 2016-04-20 广西壮族自治区化工研究院 一种蔗糖铁的制备方法
AU2015324103C1 (en) * 2014-09-29 2020-08-20 Fred Hutchinson Cancer Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
US20190106454A1 (en) * 2016-03-23 2019-04-11 Fred Hutchinson Cancer Research Center Compounds linked with a saccharide metal complex and uses thereof
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
EP4559468A3 (en) 2017-09-11 2025-06-25 Pharmacosmos Holding A/s Iron complex compounds for therapeutic use
CN109912675B (zh) 2017-12-13 2020-09-15 北京市林业果树科学研究院 一种蔗糖亚铁及其制备方法
CN110063965A (zh) 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CN112315902B (zh) 2019-08-05 2022-05-13 南京恒生制药有限公司 一种低易变铁含量蔗糖铁注射液制备方法
CN112156109A (zh) 2020-09-29 2021-01-01 神奈纳米医药技术(珠海)有限公司 氢氧化铁-糖络合物的制备方法及其应用
CA3191492A1 (en) 2020-09-29 2022-04-07 LG Bionano, LLC Methods of preparing iron complexes
CN112168844A (zh) 2020-09-29 2021-01-05 神奈纳米医药技术(珠海)有限公司 一种氢氧化铁碳水化合物复合物的制备方法
CN115531414A (zh) 2021-06-30 2022-12-30 南京恒生制药有限公司 一种新型蔗糖铁复合物及其制备方法
JP2024534172A (ja) 2021-08-27 2024-09-18 ヴァイフォー（インターナショナル）アーゲー 鉄組成物並びにそれらを作製及び使用する方法

Also Published As

Publication number Publication date
KR20210133243A (ko) 2021-11-05
CA3131596A1 (en) 2020-09-03
JP2025084949A (ja) 2025-06-03
US11292813B2 (en) 2022-04-05
JP7646750B2 (ja) 2025-03-17
ES2955019T3 (es) 2023-11-28
WO2020176894A1 (en) 2020-09-03
CN113825496A (zh) 2021-12-21
PL3930686T3 (pl) 2023-11-27
RS64652B1 (sr) 2023-10-31
JP2022522009A (ja) 2022-04-13
FI3930686T3 (fi) 2023-09-01
HRP20230989T1 (hr) 2023-12-08
HUE063182T2 (hu) 2024-01-28
US11840552B2 (en) 2023-12-12
EP4234020A3 (en) 2023-10-04
US11834471B2 (en) 2023-12-05
DK3930686T3 (da) 2023-09-11
EP3930686A1 (en) 2022-01-05
SG11202109323UA (en) 2021-09-29
JP7320611B2 (ja) 2023-08-03
EP3930686B1 (en) 2023-05-31
CN119488480A (zh) 2025-02-21
EP4234020A2 (en) 2023-08-30
SMT202300276T1 (it) 2023-11-13
US20230070012A1 (en) 2023-03-09
US20240002427A1 (en) 2024-01-04
US20200277325A1 (en) 2020-09-03
US20220242901A1 (en) 2022-08-04
CN113825496B (zh) 2024-09-27
PT3930686T (pt) 2023-09-04
SI3930686T1 (sl) 2023-11-30
AU2025230678A1 (en) 2025-10-02
JP2023139154A (ja) 2023-10-03
LT3930686T (lt) 2023-10-10

Similar Documents

Publication Publication Date Title
JP7646750B2 (ja) 新規鉄組成物及びその製造方法と使用方法
Himmelstoß et al. Long‐term colloidal and chemical stability in aqueous media of NaYF4‐type upconversion nanoparticles modified by ligand‐exchange
Tarres et al. Aqueous self‐assembly and cation selectivity of cobaltabisdicarbollide dianionic dumbbells
Singla et al. Enhancing encapsulation of hydrophobic phyto-drugs naringenin and baicalein in polymeric nano-micelles
Cappellari et al. Synthesis of ultra-small cysteine-capped gold nanoparticles by pH switching of the Au (I)–cysteine polymer
Karamjavan et al. Characterization of electronic structures on the adsorption behaviors of mercaptopurine anticancer drug from surface macromolecule calix [4] aren as adsorbent by spectral studies and DFT calculations
HK40098133A (en) Novel iron compositions and methods of making and using the same
HK40066891B (en) Novel iron compositions and methods of making and using the same
HK40066891A (en) Novel iron compositions and methods of making and using the same
HK40066204B (zh) 新型铁组合物及其制造和使用方法
HK40066204A (zh) 新型铁组合物及其制造和使用方法
Xiao et al. Uncovering the role of free lanthanum (La3+) ions and La oligomer on the surface of La (oxy) hydroxide particles for phosphate removal
Loseva et al. Interaction of binuclear zinc diethyldithiocarbamate with H [AuCl4]/2 M HCl: The preparation, supramolecular self-organization, and thermal behavior of the heteropolynuclear complex ([Au {S2CN (C2H5) 2} 2] 2 [ZnCl4]· 1/2CO (CH3) 2· 1/2CHCl3) n
Molloy et al. Self-assembly of nanocrystalline tetra-terpyridine complexes: from molecules to mesoscopic objects
Inoue et al. Inclusion complexes of Ursolic acid with Cyclodextrin-based metal-organic Framework-1 enhance its solubility
Giorgetti et al. Cu K-edge EXAFS on copper (I) complexes containing dihydridobis (3-nitro-1, 2, 4-triazol-1-yl) borate and bis (1, 2, 4-triazol-1-yl) acetate ligand: Evidence for the Cu–O interaction
Chang et al. Carbon-13 Fourier transform nuclear magnetic resonance study of gallium citrate in aqueous solution
Lebedev et al. Polarized-neutron scattering in aqueous solutions of fullerenols in a magnetic field
Lebedev et al. Biocompatible water-soluble endometallofullerenes: peculiarities of self-assembly in aqueous solutions and ordering under an applied magnetic field
Lian et al. The revolutionizing osteosarcoma therapy of carbon monoxide and doxorubicin synergy via mesoporous silica nanoparticles
Erenburg et al. Structural characteristics of amorphous K-Bi citrate (De-Nol) and its aqueous solutions from EXAFS spectra
Cardoso et al. Radiation-induced copper oxide formation in a clinical gel composite: a novel approach for dosimetry
Vasquez et al. A nanocarrier delivery system of oxaliplatin for glioblastoma: synthesis and cytotoxicity of Fe 3 O 4@ SiO 2/OXA nanocomposites
Khamms et al. Indirect electrothermal Atomization Atomic Absorption Spectrometric determination of drugs, Desfeiroxamine in some pharmaceutical preparations using vanadilium (V) as a mediatory element
Bhai Development and validation of analytical methods for estimation of citicoline in bulk and pharmaceutical formulations

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted